Do Formulation Differences Alter Abuse Liability of Methylphenidate?: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study in Recreational Drug Users
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The primary objective of this study was to determine if the abuse liability of methylphenidate is governed by formulation differences that affect rates of drug delivery. In this double-blind, placebo-controlled, randomized, crossover study, subjects with a history of recreational drug use received single oral doses of placebo, 60 mg of immediate-release methylphenidate (IR) and 108 mg of extended-release methylphenidate (osmotic release oral system [OROS]). Over 24 hours after dosing, blood was collected to determine plasma concentrations of methylphenidate, and subjects completed subjective assessments of abuse liability (Addiction Research Center Inventory, Drug Rating Questionnaire-Subject, and Subjective Drug Value). The abuse-related subjective effects of IR and OROS methylphenidate were statistically significantly different from placebo, confirming the overall validity of the study. Although a higher dose of OROS methylphenidate was used compared with IR methylphenidate (108 mg vs 60 mg), subjective effects were consistently lower for OROS compared with IR methylphenidate (statistically significant for 3 of 6 measures of positive effects), particularly at early time points. In general, pharmacokinetic-pharmacodynamic parameters were correlated from a poor to modest degree, with greater correlations observed for IR methylphenidate. In addition, a post hoc "qualification" method was developed, which demonstrated that pharmacological qualification might improve the assessment of subjective effects. Although requiring epidemiological confirmation, the results suggest that OROS methylphenidate, with its characteristic slow ascending plasma concentration profile, may have lower abuse potential. This conclusion is reflected by lower subjective responses during early hours as compared with the IR formulation with its rapid drug delivery and accompanying greater subjective effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Clinical correlates of inpatient suicide
Busch, K. A., Fawcett, J., & Jacobs, D. G. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0105 · Cited by 750
Volkow, N. D. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180042006 · Cited by 575 · cited 1×
“This is at least partly due to the pharmacokinetics of the drug (ie, slower disposition and elimination from the brain compared with other addictive drugs such as cocaine).(13,15) The formulation of a drug can significantly affect its potential for physical compromise, diversion, and abuse.”
BackgroundVariables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Volkow, N. D., & Swanson, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1909 · Cited by 475 · cited 4×
“is observed when MPH elicits large rapid extracellular dopamine increases in the central nervous system, whereas therapeutic effects occur when MPH elicits slow dopamine increases.(13,20) In addition, when more than 50% to 60% of dopamine transporters (DAT) are blocked, sustained elevations in drug concentrations lead…”
BackgroundInfluentialVolkow, N. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00104-9 · Cited by 217 · cited 2×
“is observed when MPH elicits large rapid extracellular dopamine increases in the central nervous system, whereas therapeutic effects occur when MPH elicits slow dopamine increases.(13,20) In addition, when more than 50% to 60% of dopamine transporters (DAT) are blocked, sustained elevations in drug concentrations lead…”
BackgroundStimulant medications: how to minimize their reinforcing effects?
VOLKOW, N. D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.359 · Cited by 70
Cited by
Attention‐Deficit‐Hyperactivity Disorder: An Update
Dopheide, J. A., & Pliszka, S. R. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.6.656 · Cited by 645
Understanding Attention-Deficit/Hyperactivity Disorder from Childhood to Adulthood
Wilens, T. E., & Spencer, T. J. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2206 · Cited by 324
The Potential for Misuse and Abuse of Medications in ADHD: A Review
Clemow, D. B., & Walker, D. J. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2801 · Cited by 198
Konstenius, M., Jayaram‐Lindström, N., Guterstam, J., Beck, O., Philips, B., & Franck, J. (2014) · Addiction · doi:10.1111/add.12369 · Cited by 188
“The reinforcing effects of stimulants are associated with rapid changes in serum concentration [39], and extended-release preparations of MPH are associated with less stimulant-like drug effects in healthy subjects [40].”
BackgroundEffects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial
Mooney, M. E., Herin, D. V., Schmitz, J. M., Moukaddam, N., Green, C. E., & Grabowski, J. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.016 · Cited by 124
Metadata
- Authors
- Parasrampuria, D. A., Schoedel, K. A., Schuller, R., Silber, S. A., Ciccone, P. E., Gu, J., & Sellers, E. M.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2007-10
- Volume
- 27
- Issue
- 5
- Pages
- 459-467
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2056151789
- Cited by
- 74
- References
- 7
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Do Formulation Differences Alter Abuse Liability of Methylphenidate?: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study in Recreational Drug Users. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181515205
- The paper
- Parasrampuria, D. A., Schoedel, K. A., Schuller, R., Silber, S. A., Ciccone, P. E., Gu, J., & Sellers, E. M. (2007). Do Formulation Differences Alter Abuse Liability of Methylphenidate?: A Placebo-Controlled, Randomized, Double-Blind, Crossover Study in Recreational Drug Users. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181515205
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.